MHRA positive opinion for avelumab as bladder cancer first-line maintenance treatment
UK Medicines and Healthcare Products Regulatory Agency (MHRA) has issued an Early Access to Medicines Scheme (EAMS) positive scientific opinion for avelumab as first-line...
Novo Nordisk announces new oral treatment for type 2 diabetes
Novo Nordisk has announced that Rybelsus® (semaglutide tablets), the world’s first and only oral GLP1-RA treatment for type 2 diabetes (T2D), is now available...
EU approves Imfinzi for extensive-stage small cell lung cancer
AstraZeneca has announced that the EU has approved Imfinzi (durvalumab) for the 1st-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination...
BIVDA joins Trade Advisory Group on Life Sciences
The British In Vitro Diagnostic Association has joined the new trade advisory group on life sciences. International Trade Secretary, Liz Truss, has launched 11 new...
EC approves Kaftrio® in combination to treat cystic fibrosis
The European Commission (EC) has approved Kaftrio® (ivacaftor/tezacaftor/elexacaftor) in combination with Ivacaftor to treat cystic fibrosis in people aged 12 and older. Vertex Pharmaceuticals announced...
NICE recommends new combination treatment for some lymphoma patients
NICE has recommended a new combination treatment for some lymphoma patients meaning that hundreds of people will benefit. The new draft guidance published by NICE...
Sanofi to acquire Principia Biopharma
Sanofi has announced that it is to acquire Principia Biopharma further strengthening its core R&D areas of autoimmune and allergic diseases. Sanofi and Principia Biopharma...
AstraZeneca and European Commission COVID-19 vaccine agreement
AstraZeneca has concluded an agreement with the European Commission for the supply of up to 400 million doses of AZD1222 COVID-19 vaccine. This is...
QBiotics and MSD collaborate on unresectable melanoma
QBiotics Group Limited, a life sciences company developing novel anticancer and wound healing pharmaceuticals, has entered into an agreement with MSD to evaluate use...
‘One Million’ study to monitor COVID-19 vaccine safety and effectiveness
A UK consortium has announced plans for a 'One Million' Post-Authorisation Study to monitor the safety and effectiveness of the COVID-19 vaccine in real-life...
Latest articles
Partnership announced to fight against counterfeit drugs
Advanco and Syntegon have announced a strategic partnership, marking a significant step towards helping to eradicate the growing problem of counterfeit drugs. The counterfeit...
GSK receives CHMP positive opinion for Zejula▼(niraparib)
GSK receives CHMP positive opinion recommending approval of Zejula▼(niraparib) as first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer. GlaxoSmithKline (GSK) plc announced...
WAYLIVRA▼® (volanesorsen) for FCS to be available on the NHS in England
The National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for WAYLIVRA▼® (volanesorsen), the first and only therapy for adults...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Rapid COVID-19 diagnostic test to be deployed in hospitals
A new rapid COVID-19 diagnostic test developed by a University of Cambridge spinout company and capable of diagnosing the infection in under 90 minutes,...
GSK receives CHMP positive opinion for Zejula▼(niraparib)
GSK receives CHMP positive opinion recommending approval of Zejula▼(niraparib) as first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer. GlaxoSmithKline (GSK) plc announced...
Understanding the role of the MSL
Helen Kane surveyed more than 200 medical science liaisons (MSLs) to understand more about their current in-role reality. She gave Pf Magazine exclusive access...
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...